Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma has addressed market speculation following an FDA ‘untitled letter’ concerning promotional claims for its contraceptive product, NEXTSTELLIS®. The company has voluntarily withdrawn the presentation in question but states that the letter does not affect its ability to sell NEXTSTELLIS® in the U.S. or impact its stock price. Mayne Pharma plans to proceed with its Scheme of Arrangement with Cosette as scheduled.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also offers contract development and manufacturing services globally and has a strong history of innovation in oral drug delivery systems.
Average Trading Volume: 797,278
Technical Sentiment Signal: Hold
Current Market Cap: A$560.6M
For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.